January 31, 2008
UCD Chemistry Graduate Appointed New CEO of Celtic Catalysts

Dr Brian Kelly has been appointed CEO of NovaUCD-based Celtic Catalysts. He replaces current CEO Brian Elliott who has been appointed Chairman of the Board of Directors. Celtic Catalysts is a leading supplier of chiral products and technology to the Fine Chemical, Pharmaceutical and Biotech industries.

Dr Brian Kelly and Professor Declan Gilheany
Dr Brian Kelly, CEO Celtic Catalysts and Professor Declan Gilheany,
UCD School of Chemistry and Chemical Biology

Dr Brian Kelly and CSCB researcher Professor Declan Gilheany co-founded Celtic Catalysts in 2000 as a spin-out from UCD’s School of Chemistry and Chemical Biology. Brian graduated from University College Dublin in 2000 with a PhD in organic chemistry. He has been Celtic Catalysts’ Director of Business Development since then. Celtic Catalysts currently employs 17 and is headquartered in NovaUCD, the Innovation and Technology Transfer Centre at UCD.

Celtic Catalysts focuses on the area of asymmetric synthesis and has developed a comprehensive portfolio of intellectual property and has carved out a uniquely strong niche for itself in the specialised area of P-chiral technology.  This technology can be used in the production of a range of phosphorus nucleotide drugs – which are particularly prevalent in anti-viral and anti-cancer therapeutic areas. Celtic Catalysts undertakes its own in house research and development programmes and works with several major pharma companies in developing new synthetic routes to manufacture existing drugs or drugs in development.

 

 

More News